RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Utilization of the 21-Gene Rs Test Among Medicare Beneficiaries with Breast Cancer in 2011
Lynch, J., Berse, B., Coomer, N., & Kautter, J. (2016). Utilization of the 21-Gene Rs Test Among Medicare Beneficiaries with Breast Cancer in 2011. Value in Health, 19(3), A165. https://doi.org/10.1016/j.jval.2016.03.1510
Despite widespread implementation of the 21-gene test, some minorities and Medicaid patients have less access to testing. We also identified patients for whom the appropriateness of testing was questionable due to comorbid medical conditions or advanced age. Our data illustrate the need to improve coding to ensure that reimbursement of genomic tests is tied to appropriate use and to discourage overutilization.
